- Company
- Yuyu Pharma rewards stock grant valued at KRW 500 million
- by Lee, Seok-Jun Jan 9, 2020 06:25am
- This year again, Yuyu Pharma granted the company’s stock to its employee as an incentive award. Since July 2017, the pharmaceutical company has been granting shares of the company stock to selected top employees, biannually. Employees rewarded with the stock grant can immediately liquidate it as they directly receive the share the company o
- Policy
- ATP-based reduction on immunosuppressant Certican
- by Kim, Jung-Ju Jan 9, 2020 06:24am
- Price of Novartis’ immunosuppressant Certican (everolimus), still in prolonged pricing reduction cancellation litigation with the government, would be reduced based on actual transaction price (ATP) survey result. The pricing reduction on Certican would be enforced after the ongoing litigation reaches its final decision as it still has admi
- Opinion
- [FOCUS] Pharmaceutical bio-industry in the Middle of Change
- by Kim, Jung-Ju Jan 8, 2020 08:10pm
- This year, the Ministry of Health and Welfare increased the pharmaceutical bio industry support budget by two digits in each sector. The AI &8203;&8203;drug development platform construction support division has successfully allocated &8361;2.8 billion, up &8361;300 million (11.1%) from last year's &8361;2.5 billion, and support for t
- Policy
- Reevaluation to first review underperforming drug
- by Kim, Jung-Ju Jan 8, 2020 06:19am
- The government reaffirmed the listed drug reevaluation subject would prioritize drugs with clinical efficacy underperforming than initially expected. Gradually conducted on all subjected drugs, actions following up the reevaluation, such as pricing reduction or reimbursed indication revocation or reduction on drug not reaching expected e
- Company
- Near miss, tension in the Middle East
- by Kim, Jin-Gu Jan 8, 2020 06:18am
- Amid rising military tensions between the United States and Iran, there is also concern about bad influence on trade between Korea and Iran. In the case of drugs, exports have already been blocked since last year. There is also concern that the resumption of exports will be postponed indefinitely. According to the Korea Customs Service's i
- Policy
- Generic pricing should be at original’s 40%-45%
- by Lee, Hye-Kyung Jan 8, 2020 06:17am
- The national insurer’s research result claims the volume of generic would increase up to 73 percent to 82 percent if the use of generic is promoted, if the present lump-sum generic pricing reduction is brought down to 40 percent or 45 percent of the original price before patent expiration. Currently, the lump-sum pricing reduction drops generic
- Company
- Tension on impurity diabetic drugs is for a month
- by Chon, Seung-Hyun Jan 8, 2020 06:17am
- It's been a month since concerns of impurity Metformin were triggered overseas, but there are still no clear conclusions. Expectations are raised in the pharmaceutical industry that there is no recovery country other than Singapore and that it can only be a surprise. However, there is still a lot of tension that if there is a recovery fr
- Policy
- China's "New Law" tightens safety and quality management
- by Kim, Jung-Ju Jan 8, 2020 06:15am
- China is to reinforce overall pharmaceutical management and monitoring regulation covering from pharmaceutical production, launch, clinical trial to counterfeit drug. The so-called ‘New Drug Administration Law’ would mainly focus on safety and quality. China’s National Medical Products Administration (NMPA) had taken the revised law i
- Company
- Pfizer Korea is looking for a new office
- by Kim, Jin-Gu Jan 7, 2020 06:29am
- Pfizer Korea is pursuing the sale of its Myeong-dong office, which has stayed for the past 13 years. Location of new office is planning Yeouido, Jamsil or Pangyo. According to the pharmaceutical industry on the 6th, Pfizer Korea is considering the sale of its office and relocation of its office. Currently, Pfizer Korea is located at 110
- Company
- SNU professor investigates new anti-cholesterol medicine
- by Eo, Yun-Ho Jan 7, 2020 06:29am
- Researchers in Korea are onto developing a next generation anti-cholesterol medicine. Pharmaceutical industry reported on Jan. 7, a team of Seoul National University researchers led by Professor Kim Hyo-soo is preparing a Phase 1 clinical study on candidate medicine inhibiting cyclase-associated protein 1 (CAP1). Previously, Seoul N
